Results 221 to 230 of about 100,065 (334)

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Trends in U.S. Adolescent Use of Vaping and Flavored Solutions for Marijuana Consumption, 2021-2024. [PDF]

J Adolesc Health
Miech R, Patrick ME, Leventhal AM.
europepmc   +1 more source

Associations Between Marijuana Use Trajectories and Educational and Occupational Success in Young Adulthood [PDF]

, 2018
Kara Thompson, Bonnie J. Leadbeater, Megan E. Ames, Gabriel J. Merrin   +3 more
openalex   +1 more source

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

Addiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring, Tom Tidhar, Anna Olsen, Christopher Bailie, Kelvin Burke, Rowan Martin‐Hughes, Helen Keane, Paul Dietze, Nick Scott   +8 more
wiley   +1 more source

Marijuana Liberalization and Executive Mobility: Evidence from State-Level Policy Changes

Xin Chen, Albert Tsang, Shuo Yan
openalex   +1 more source

Marijuana and Youth

, 2000
Rosalie Liccardo Pacula, Michael Grossman, Frank J. Chaloupka, Patrick M. O’Malley, Lloyd D. Johnston, Matthew C. Farrelly   +5 more
openalex   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Medical marijuana policies, opioid prescriptions, and adverse events among patients undergoing cancer resection surgery. [PDF]

Cancer
Hu JC, Karan K, Zhang H, Portenoy R, Rosa WE, Zhang Y, Reid MC, Tamimi RM, Zhang F, Bruera E, Paice JA, Bao Y.   +11 more
europepmc   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Effect of Marijuana Use on Pain Management and Return to Sport After Anterior Cruciate Ligament Reconstruction in Pediatric and Adolescent Patients: A Matched Control Study. [PDF]

Orthop J Sports Med
Franco H, Farid AR, De Silva S, Guevel B, Kocher MS, Hogue GD.   +5 more
europepmc   +1 more source